

OncoScan[®] FFPE assay publications 2011 to November 2014

2014

Kohsaka S., *et al.* A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal. *Nature Genetics* **46**:595–600 (2014). doi:10.1038/ng.2969

Ruland V., *et al.* Choroid plexus carcinomas are characterized by complex chromosomal alterations related to patient age and prognosis. *Genes, Chromosomes & Cancer* **53**(5):373–380 (2014). doi:10.1002/gcc.22148

Bellido F., *et al.* Comprehensive molecular characterization of hereditary non-polyposis colorectal tumors with mismatch repair proficiency. *European Journal of Cancer* **50**(11):1964–1972 (2014). doi:10.1016/j.ejca.2014.04.022

Guancial E. A., *et al.* FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder. *Cancer Medicine* (2014). doi:10.1002/cam4.262

Hunter S. M., *et al.* Genomic aberrations of BRCA1-mutated fallopian tube carcinomas. *The American Journal of Pathology* **184**(6):1871–1876 (2014). doi:10.1016/j.ajpath.2014.02.013

Riester M., *et al.* Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma. *Clinical Cancer Research* **20**(7):1873–1883 (2014). doi:10.1158/1078-0432.CCR-13-0759

Thompson, P. A. *et al.* Loss of LRIG1 locus increases risk of early and late relapse of stage I/II breast cancer. *Cancer Research* **174**(11):2928–2935 (2014). doi:10.1158/0008-5472.CAN-13-2112

Goschzik T., *et al.* Molecular stratification of medulloblastoma: comparison of histological and genetic methods to detect Wnt activated tumors. *Neuropathology and Applied Neurobiology* (2014). doi:10.1111/nan.12161

Gessi M., *et al.* MYCN amplification predicts poor outcome for patients with supratentorial primitive neuroectodermal tumors of the central nervous system. *Neuro-Oncology* (2014). doi:10.1093/neuonc/not302

Tan W. J., *et al.* Novel genetic aberrations in breast phyllodes tumors: comparison between prognostically distinct groups. *Breast Cancer Research Treatment* **145**(3):635–645 (2014). doi:10.1007/s10549-014-2982-y

2013

Hosein A. N., *et al.* Evaluating the repair of DNA derived from formalin-fixed paraffin-embedded issues prior to genomic profiling by SNP–CGH analysis. *Laboratory Investigation* **93**(6):701–710 (2013). doi:10.1038/labinvest.2013.54

Gonzalez-Angulo A. M., *et al.* Frequency of mesenchymal-epithelial transition factor gene (MET) and the in catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer. *Cancer* **119**(1):7–15 (2013). doi:10.1002/cncr.27608.

Gessi M., *et al.* H3.3 G34R mutations in pediatric primitive neuroectodermal tumors of central nervous system (CNS-PNET) and pediatric glioblastomas: possible diagnostic and therapeutic implications? *Journal of Neuro-Oncology* **112**(1):67–72 (2013). doi:10.1007/s11060-012-1040-z

Salaverria I., *et al.* High resolution copy number analysis of IRF4 translocation-positive diffuse large B-cell and follicular lymphomas. *Genes, Chromosomes & Cancer* **52**(2):150–155 (2013). doi:10.1002/gcc.22014

Hasselblatt M., *et al.* High-resolution genomic analysis suggests the absence of recurrent genomic alterations other than SMARCB1 aberrations in atypical teratoid/rhabdoid tumors. *Genes, Chromosomes & Cancer* **52**(2):185–190 (2013). doi:10.1002/gcc.22018.

Nguyen, T. L., *et al.* Mitotically active proliferative nodule arising in a giant congenital melanocytic nevus: a diagnostic pitfall. *American Journal of Dermatopathology* **35**(1):e16–e21 (2013). doi:10.1097/DAD.0b013e318265fe12

Belinsky M. G., *et al.* Overexpression of insulin-like growth factor 1 receptor and frequent mutational inactivation of SDHA in wild-type SDHB-negative gastrointestinal stromal tumors. *Genes, Chromosomes & Cancer* **52**(2):214–224 (2013). doi:10.1002/gcc.22023

Martin-Guerrero I., *et al.* Recurrent loss of heterozygosity in 1p36 associated with TNFRSF14 mutations in IRF4 translocation negative pediatric follicular lymphomas. *Haematologia* **98**(8):1237–1241 (2013). doi:10.3324/haematol.2012.073916

Mao M., *et al.* Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. *Clinical Cancer Research* **19**(3):657–667 (2013). doi:10.1158/1078-0432.CCR-11-1446

2012

Xie T., *et al.* A comprehensive characterization of genome-wide copy number aberrations in colorectal cancer reveals novel oncogenes and patterns of alterations. *PLoS One* **7**(7):e42001 (2012). doi:10.1371/journal.pone.0042001

Ho J. E., *et al.* Clinical and genetic correlates of growth differentiation factor 15 in the community. *Clinical Chemistry* **58**(11):158–291 (2012). doi:10.1373/clinchem.2012.190322

Chandler W. M., *et al.* Differentiation of malignant melanoma from benign nevus using a novel genomic microarray with low specimen requirements. *Archives of Pathology & Laboratory Medicine* **136**(8):947–955 (2012). doi:10.5858/arpa.2011-0330-OA

Sadanandam A., *et al.* Genomic aberrations in normal tissue adjacent to HER2-amplified breast cancers: field cancerization or contaminating tumor cells? *Breast Cancer Research and Treatment* **136**(3):693–703 (2012). doi:10.1007/s10549-012-2290-3.

Charbonneau B., *et al.* Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell lymphoma. *American Journal of Hematology* **87**(9):880–885 (2012). doi:10.1002/ajh.23273.

Skirnisdottir I., *et al.* Loss-of-heterozygosity on chromosome 19q in early-stage serous ovarian cancer is associated with recurrent disease. *BMC Cancer* **12**(1):407 (2012).

Harris K., *et al.* Melanoma Mimic: A Case of Multiple Pagetoid Spitz Nevi. *Archives of Dermatology* **148**(3):370–374 (2012).

Mona S., *et al.* Molecular inversion probe analysis detects novel copy number alterations in Ewing sarcoma. *Cancer Genetics* **205**(7-8):391–404 (2012).

Wang Y., Cottman M., Schiffman J. D. Molecular inversion probes: a novel microarray technology and its application in cancer research. *Cancer Genetics* **205**(7-8):341–355 (2012).

Nicolai J., *et al.* Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents. *Cancer Discovery* **2**(4):366–375 (2012).

Leventaki V., *et al.* TP53 pathway analysis in pediatric Burkitt lymphoma reveals increased MDM4 expression as the only TP53 pathway abnormality detected in a subset of cases. *British Journal of Haematology* **158**(6):763–771 (2012). doi:10.1111/j.1365-2141.2012.09243.

2011

Hunter S. M., *et al.* Copy Number Aberrations in Benign Serous Ovarian Tumors: A Case for Reclassification? *Clinical Cancer Research* **17**(23):7273–7282 (2011).

Jahromi M. S., Jones K. B., Schiffman J. D. Copy Number Alterations and Methylation in Ewing's Sarcoma. *Sarcoma* 2011;2011:362173. Epub Mar 15 (2011).

Brewster A. M., *et al.* Copy Number Imbalances between Screen- and Symptom-Detected Breast Cancers and Impact on Disease-Free Survival. *Cancer Prevention Research* **4**(10):1609–1616 (2011).

Geiersbach K. B., *et al.* FOXL2 mutation and large-scale genomic imbalances in adult granulosa cell tumors of the ovary. *Cancer Genetics* **204**(11):596–602 (2011).

Schiffman J. D., *et al.* Genome wide copy number analysis of pediatric Burkitt lymphoma using formalin-fixed tissues reveals a subset with gain of chromosome 13q and corresponding miRNA over expression. *British Journal of Haematology* **155**(4):477–486 (2011).

Beeghly-Fadiel A., *et al.* MMP9 polymorphisms and breast cancer risk: a report from the Shanghai Breast Cancer Genetics Study. *Breast Cancer Research and Treatment* **126**(2):507–513 (2011).

Thompson P. A., *et al.* Selective genomic copy number imbalances and probability of recurrence in early-stage breast cancer. *PLoS One* **6**(8):e23543 (2011).

Geiersbach K., *et al.* Unknown partner for USP6 and unusual SS18 rearrangement detected by fluorescence *in situ* hybridization in a solid aneurysmal bone cyst. *Cancer Genetics* **204**(4):195–202 (2011).